ArticleFrontiers in digital health2021
Personalised, Rational, Efficacy-Driven Cancer Drug Dosing
Article in Frontiers in digital health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial Intelligence and Decision-Making in Oncology: A Review of Ethical, Legal, and Informed Consent Challenges.Current oncology reports · 2025Pooled it
- Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology.Materials today. Bio · 2026Review
- Algorithm-assisted individualized therapy design improves survival in a mouse model of triple-negative breast cancer.NPJ precision oncology · 2026Article
- Artificial intelligence for breast cancer management.Communications medicine · 2026Review
- AI-assisted warfarin dose optimisation with CURATE.AI for clinical impact: Retrospective data analysis.Bioengineering & translational medicine · 2025Article
- Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial.NPJ precision oncology · 2025Article
- A Comprehensive Investigation: Developing the Pharmaceutical Industry through Artificial Intelligence.Current drug discovery technologies · 2025Review
- Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial.NPJ digital medicine · 2024Article
- N-of-1 medicine.Singapore medical journal · 2024Article
- Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine.PLoS computational biology · 2024Article
- Physicians' Perspectives on AI in Clinical Decision Support Systems: Interview Study of the CURATE.AI Personalized Dose Optimization Platform.JMIR human factors · 2023Article
- The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens.NPJ digital medicine · 2022Article
- Article
- N-of-1 Healthcare: Challenges and Prospects for the Future of Personalized Medicine.Frontiers in digital health · 2022Article
- Artificial intelligence in modern clinical practice (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.